Ibrutinib-Venetoclax-Obinutuzumab for Richter Transformation
May 5, 2025
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
As more and more drugs have become available to treat CLL, doctors and patients alike want to know what is the best way to sequence these therapies.
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.
Richter’s transformation is a rare very aggressive complication of CLL. Learn the role of stem cell transplants in treating Richter’s transformation.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
One year after Dr. Brian Koffman enrolled as the first chronic lymphocytic leukemia (CLL) patient in the epcoritamab clinical trial, all is well.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.